Rituximab is not Superior in EGPA Save
A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.
This was a Phase 3, multicenter, randomized, controlled, double-blind, superiority trial that included 105 active EGPA patients (BVAS > 3) treated with either Glucocorticoids plus rituximab (1 g 2 weeks apart) compared with the conventional strategy (glucocorticoids alone or in combination with cyclophosphamide in severe forms) for induction of remission. The primary end point was remission defined as a BVAS, version 3, of 0 and a prednisone dose of 7.5 mg/d or less at day 180.
The primary endpoint at 6 months:
- RTX: 63.5% (mean duration of remission was 48.5 ± 6.51 weeks)
- Conventional Rx; 60.4% (mean duration of remission 49.1 ± 7.42 weeks)
- (RR 1.05 [95% CI, 0.78 to 1.42]; P = 0.75).
- Results were similar at day 360. i
There was no difference in the average daily glucocorticoid dose or adverse events between groups.
Rituximab was not superior to a conventional remission induction strategy in EGPA.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.